Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses

ClinicalTrials.gov ID: NCT02120898

Public ClinicalTrials.gov record NCT02120898. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of Generic Imiquimod Cream, 2.5% and Zyclara® (Imiquimod) Cream, 2.5% in Subjects With Actinic Keratoses

Study identification

NCT ID
NCT02120898
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Actavis Inc.
Industry
Enrollment
467 participants

Conditions and interventions

Interventions

  • Imiquimod Drug
  • Zyclara® Drug
  • Vehicle Cream Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 9, 2013
Primary completion
Apr 29, 2014
Completion
Apr 29, 2014
Last update posted
Dec 12, 2019

2013 – 2014

United States locations

U.S. sites
27
U.S. states
15
U.S. cities
26
Facility City State ZIP Site status
Site 1 Birmingham Alabama 35025
Site 10 Fremont California 94538
Site 8 Los Angeles California 90045
Site 24 Denver Colorado 80220
Site 28 Boca Raton Florida 33486
Site 26 Brandon Florida 33511
Site 27 Brandon Florida 33511
Site 21 Boise Idaho 83704
Site 3 Arlington Heights Illinois 60005
Site 17 Champaign Illinois 61820
Site 7 Carmel Indiana 46032
Site 15 Indianapolis Indiana 46256
Site 22 Plainfield Indiana 46168
Site 23 South Bend Indiana 46617
Site 16 Clinton Township Michigan 48038
Site 13 Fridley Minnesota 55432
Site 9 Albuquerque New Mexico 87106
Site 4 High Point North Carolina 27262
Site 11 Wilmington North Carolina 28403
Site 18 Winston-Salem North Carolina 27103
Site 25 Portland Oregon 97223
Site 20 Fountain Inn South Carolina 29644
Site 6 Knoxville Tennessee 37917
Site 5 Nashville Tennessee 37203
Site 14 Austin Texas 78759
Site 12 College Station Texas 77845
Site 2 Houston Texas 77056

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02120898, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 12, 2019 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02120898 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →